All Hybrid Industry Symposia
Saturday, 10 July 2021
Company Sponsored Symposia (CSS) / Satellite Symposia (SAT) / Company Sponsored Mini Symposia (CSMS)
All Hybrid Symposia are located at ICE Krakow in Hall S2 and are also available on the EAACI Hybrid Congress 2021 digital platform.
CSMS 1-1
09:00 – 09:30
AstraZeneca: Relegating OCS to last resort: Creating a paradigm shift in asthma management
OCS use in asthma – what is the problem, and why does it matter?
Speaker: Jorge Maspero, Argentina
Identifying severe and uncontrolled asthma – tools for improving clinical care
Speaker: Steve Holmes, UK
Panel discussion: Driving OCS stewardship in clinical practice
Speakers: Jorge Maspero, Argentina; Steve Holmes, UK
CSS 1-1
10:00 – 11:30
ALK: Best in both worlds – Demonstrating long-term effectiveness of allergy immunotherapy in the real world
Chair: Natalija Novak, Germany
REWEAL: REal World Evidence in Allergy
Speaker: Natalija Novak, Germany
Randomised controlled trials: The start of our evidence-based journey
Speaker: Stephen R. Durham, UK
Real world evidence: New horizons, and reasons to believe
Speaker: Nick Freemantle, UK
The big REWEAL: Real patients. Real questions. Answered!
Speaker: Benedikt Fritzsching, Germany
Panel discussion
Speaker: All
CSS 1-2
12:00 – 13:30
AMGEN and AstraZeneca: TSLP: a key epithelial cytokine at the top of the asthma inflammatory cascade
Chairs: Andrew Menzies-Gow, UK & Stephanie Korn, Germany
Raising the bar for the management of severe asthma: remission as the goal of therapy
Speaker: Andrew Menzies-Gow, UK
The airway epithelium as first line of defence: diverse downstream inflammatory cascades in response to viruses and allergens
Speaker: Celeste Porsbjerg, Denmark
Triggers of exacerbations: what is driving severe asthma?
Speaker: Stephanie Korn, Germany
How might epithelial cytokines be driving asthma in our patients?
Speaker: Ioana Agache, Romania
Audience Q&A, discussion and concluding remarks
Andrew Menzies-Gow, UK; Stephanie Kom, Germany; Ioana Agache, Romania
CSS 1-3
14:00 – 15:30
Thermo Fisher Scientific: Asthma, does allergy matter?
Chair: Pablo Rodríguez del Río, Spain
Welcome and introduction
Speaker: Pablo Rodríguez del Río, Spain
Every doctor should phenotype asthmatic patients
Speaker: Thomas Casale, USA
How to improve management and care for the wheezing child
Speaker: Andrew Liu, USA
Updates in allergen component testing and what’s in the pipeline
Speaker: Magnus Borres, Sweden
Q&A
Speakers: Pablo Rodríguez del Río, Spain; Thomas Casale, USA; Andrew Liu, USA; Magnus Borres, Sweden
CSS 1-4
16:00 – 17:30
Sanofi Genzyme and Regeneron: Navigating Type 2 Inflammation across the skin, airway, and esophagus
Chair: William Busse, USA
Connecting Type 2 Inflammation to clinical characteristics of disease
Speaker: Oscar Palomares, Spain
Breaking barriers: How relevant are biomarkers of Type 2 Inflammation?
Speaker: William Busse, USA
Clinical implications: Why target Type 2 Inflammation?
Speakers: Natalija Novak, Germany & William Busse, USA
Question and answer session
Speakers: All Faculty
SAT 1-1
18:00 – 19:00
GSK: Targeted therapy for patients with severe eosinophilic asthma – an interactive conversation with experts
Chairs: Peter Howarth, UK; Maciej Kupczyk, Poland
Welcome address from chairs
Speakers: Peter Howarth, UK; Maciej Kupczyk, Poland
Elevating care for severe eosinophilic asthma patients through precision medicine
Speaker: Santiago Quirce, Spain
Addressing your clinical questions in the treatment of severe eosinophilic asthma: Audience-led discussion
Speakers: Peter Howarth, UK; Maciej Kupczyk, Poland
Closing remarks and Q&A
Speakers: Peter Howarth, UK; Maciej Kupczyk, Poland
Sunday, 11 July 2021
CSMS 2-1
09:00 – 09:30
Allergy Therapeutics: Ameliorating atopy by targeted micronutrient supplementation with beta-lactoglobulin
Ameliorating atopy by targeted micronutrient supplementation with beta-lactoglobulin
Speaker: Franziska Roth-Walter, Austria
CSS 2-1
10:00 – 11:30
Stallergenes Greer: Supporting individual patients’ needs: AIT still an unmatched model of personalized medicine for allergy
Chairs: Giorgio Walter Canonica, Italy; Ruby Pawankar, Japan; Marek Jutel, Poland
AIT still a unique model of personalized medicine
Speaker: Giorgio Walter Canonica, Italy
Maximizing patient’s chances of better outcomes
Speaker: Oliver Pfaar, Germany
Harnessing each patient’s clinical profile in real life to adapt AIT
Speaker: Davide Caimmi, France
Making the digital shift in respiratory allergies
Speaker: Jean Bousquet, Germany
CSS 2-2
12:00 – 13:30
DBV Technologies: Patients with peanut allergy: the hope for a better life?
Chairs: Antonella Muraro, Italy; Philippe Eigenmann, Switzerland
Introduction
Speaker: Antonella Muraro, Italy
The daily burden of peanut allergy
Speaker: Katharina Blümchen, Germany
Early management of peanut allergy: the window of opportunity?
Speaker: Jonathan Hourihane, Ireland
Managing patients with peanut allergy today and tomorrow
Speaker: Helen Brough, UK
Conclusion
Speaker: Philippe Eigenmann, Switzerland
SAT 2-1
14:00 – 15:00
Sanofi Genzyme and Regeneron: Yesterday’s vision is today’s opportunity to address Type 2 Inflammation in pediatric and adult atopic dermatitis patients
Introduction
Speaker: Tilo Biedermann, Germany
Common underlying pathophysiology of Type 2 Inflammatory diseases and implications for atopic dermatitis
Speaker: Tilo Biedermann, Germany
Evolving treatments for Type 2 Inflammation in atopic dermatitis across age groups
Speaker: Lisa Beck, USA
Live Q&A
Speakers: Tilo Biedermann, Germany; Lisa Beck, USA
CSMS 2-2
15:15 – 15:45
Allergopharma: Allergen composition of preparations translate into clinical outcomes of AIT
Chair: Susanne Lau, Germany
Relevance of molecular evolution in allergic patients
Speaker: Marek Jutel, Poland
Characterizing the allergen symphony of AIT products
Speaker: Petra Zieglmayer, Austria
CSS 2-3
16:00 – 17:30
LETI Pharma: The complex world of allergy. Patient’s needs in real life
Chair: Luis Delgado, Portugal
Allergic patients: The complexity of personalized medicine
Speaker: Jeronimo Carnés, Spain
The future is now: Biomarkers
Speaker: Mohamed Shamji, U.K
RWE: What is happening with our patients?
Speaker: Ralph Mösges, Germany
IWS 2-1
Hall S3A (100 pax) / Channel 3 – EAACI Lab1
17:15 – 18:45
HAL Allergy: Meet the experts on AIT in Food Allergy
Welcome & Introduction
Current Developments of AIT in Food Allergies
Speaker: Ronald van Ree, The Netherlands
Who are the right candidates for AIT in food allergy?
Speaker: Montserrat Fernandez Rivas, Spain
Q & A Podium Discussion
Speakers: Ronald van Ree, The Netherlands; Montserrat Fernandez Rivas, Spain
SAT 2-2
18:00 – 19:00
Sanofi Genzyme and Regeneron: Managing severe asthma and CRSwNP: Through the lens of Type 2 Inflammation
Chairs: Santiago Quirce, Spain; Ekkehard Beck, Germany; Enrico Heffler, Italy; Wytske J. Fokkens, The Netherlands
Opening Remarks
Speakers: Santiago Quirce, Spain; Ekkehard Beck, Germany; Enrico Heffler, Italy
Wytske J. Fokkens, The Netherlands
Type 2 Inflammation: The common underlying pathway
Speaker: Enrico Heffler, Italy
Panel discussion: What have we learned about Type 2 Inflammation from clinical experience?
Speakers: Santiago Quirce, Spain; Ekkehard Beck, Germany; Enrico Heffler, Italy; Wytske J. Fokkens, The Netherlands
Dupilumab: Targeting Type 2 Inflammation to effectively treat asthma and CRSwNP
Speakers: Ekkehard Beck, Germany; Wytske J. Fokkens, The Netherlands
Audience Q&A – Closing remarks
Speakers: Santiago Quirce, Spain; Ekkehard Beck, Germany; Enrico Heffler, Italy; Wytske J. Fokkens, The Netherlands
Monday, 12 July 2021
SAT 3-1
10:15 – 11:15
Nestlé Health Science: Advancing the management of CMPA with HMO: Priming the immune system
Chair: Liam O’Mahony, Ireland
Introduction
Speaker: Liam O’Mahony, Ireland
The clinical relevance of HMO in infants with CMPA
Speaker: Yvan Vandenplas, Belgium
HMO shaping the gut microbiome in infants with CMPA
Speaker: Ralf Heine, Switzerland
Immunological and microbial effects of HMO in experimental models of food allergy
Speaker: Sophie Nutten, Switzerland
CSS 3-1
12:00 – 13:30
AstraZeneca: Advances in eosinophilic diseases
Chair: David Jackson, UK
Introduction to the role of esinophils in health and their role in airway inflammation
Speaker: David Jackson, UK
The central role of eosinophils in eosinophilic oesophagitis
Speaker: Arjan Bredenoord, Netherlands
The emerging role of esinophils in chronic urticaria
Speaker: Sabine Altrichter, Austria
Q&A session and meeting close
Speakers: David Jackson, UK; Arjan Bredenoord, Netherlands; Sabine Altrichter, Austria